Strides Pharma Science Ltd Stock Price Today (NSE: STAR)
Fundamental Score
Strides Pharma Science Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Strides Pharma Science Ltd share price today is ₹1106.90, up +0.38% on NSE/BSE as of 17 June 2026. Strides Pharma Science Ltd (STAR) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹8.41K (Cr). The 52-week high for STAR share price is ₹1231.00 and the 52-week low is ₹768.65. At a P/E ratio of 19.35x, STAR is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 150.67% and a debt-to-equity ratio of 0.67.
Strides Pharma Science Ltd Share Price Chart — NSE/BSE Historical Performance
Strides Pharma Science Ltd share price chart: 4.41% return over the past month. 52-week high ₹1231.00, 52-week low ₹768.65.
Strides Pharma Science Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1094.00 | ₹1094.10 | ₹1060.30 | ₹1075.00 | 2.14L (Cr) | |
| ₹1111.80 | ₹1136.30 | ₹1086.40 | ₹1094.10 | 1.89L (Cr) | |
| ₹1157.70 | ₹1168.80 | ₹1089.00 | ₹1111.80 | 5.19L (Cr) | |
| ₹1179.20 | ₹1188.00 | ₹1149.60 | ₹1154.40 | 1.80L (Cr) | |
| ₹1188.10 | ₹1207.60 | ₹1161.00 | ₹1169.20 | 2.75L (Cr) | |
| ₹1144.00 | ₹1195.00 | ₹1144.00 | ₹1188.10 | 2.59L (Cr) | |
| ₹1159.20 | ₹1169.70 | ₹1137.90 | ₹1153.20 | 1.50L (Cr) | |
| ₹1160.30 | ₹1173.30 | ₹1131.10 | ₹1159.10 | 2.19L (Cr) | |
| ₹1152.50 | ₹1210.80 | ₹1131.50 | ₹1141.70 | 6.45L (Cr) | |
| ₹1124.00 | ₹1159.00 | ₹1035.00 | ₹1153.60 | 13.25L (Cr) |
Strides Pharma Science Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1111.80 | ₹1136.30 | ₹1060.30 | ₹1075.00 | -3.31% | |
| ₹1053.30 | ₹1231.00 | ₹1017.10 | ₹1111.80 | +5.55% | |
| ₹956.00 | ₹1107.00 | ₹925.00 | ₹1036.80 | +8.45% | |
| ₹820.10 | ₹952.85 | ₹817.25 | ₹937.75 | +14.35% | |
| ₹855.00 | ₹912.00 | ₹812.00 | ₹851.55 | -0.40% | |
| ₹906.35 | ₹1010.30 | ₹768.65 | ₹877.00 | -3.24% | |
| ₹886.95 | ₹973.90 | ₹836.75 | ₹900.35 | +1.51% | |
| ₹934.40 | ₹1025.00 | ₹870.60 | ₹878.40 | -5.99% | |
| ₹820.00 | ₹978.40 | ₹792.00 | ₹934.70 | +13.99% | |
| ₹864.50 | ₹936.00 | ₹786.80 | ₹820.60 | -5.08% | |
| ₹873.00 | ₹935.00 | ₹783.15 | ₹863.70 | -1.07% | |
| ₹899.65 | ₹972.00 | ₹861.05 | ₹874.10 | -2.84% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Strides Pharma Science Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Strides Pharma Science Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of STAR across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Return on Equity (150.67%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Attractive Valuation (P/E: 19.35 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (79.67%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Excellent EPS Growth (122.76% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (124.04% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Cash Generation (₹1000.52 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 41.49%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
2 factors identified
Low Promoter Commitment (27.86%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
High Share Pledging Risk (44.13%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
Strides Pharma Science Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Strides Pharma Science Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
31.7/100 | ₹1106.90₹1107 | ₹8407.98₹8407.98 | 19.35Average 19.4 Average | 150.67%Excellent 150.67% Excellent | 14.68%Average 14.68% Average | 0.67Good 0.7 Good | 124.04%Excellent 124.04% Excellent | 10.65%Good 10.65% Good | 0.44% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Strides Pharma Science Ltd PE Ratio History
Historical price-to-earnings ratio for STAR — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹390.50 | ₹900.35 | 2.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Strides Pharma Science Ltd Dividend History
Annual cash dividends paid by STAR — dividend yield 0.44%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹22.99 Cr |
| FY 2024 | ₹13.52 Cr |
| FY 2022 | ₹22.43 Cr |
| FY 2021 | ₹17.91 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Strides Pharma Science Ltd Quarterly Performance
Latest quarterly metrics for STAR — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
4.62%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
79.67%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
10.65%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
124.04%
Compounded annual net profit growth over 5 years
Strides Pharma Science Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for STAR — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Strides Pharma Science Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Strides Pharma Science Ltd (STAR) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Strides Pharma Science Ltd
About STAR (Strides Pharma Science Ltd)
Strides Pharma Science Ltd is a global pharmaceutical entity carving a niche through its broad spectrum of development, manufacturing, and commercialization of diverse pharmaceutic...al products. It operates across a wide geographical footprint, strategically positioning itself in key markets across Africa, Australia, North America, Europe, and Asia. The company excels in producing a comprehensive range of finished dosage forms, catering to various therapeutic needs through an array of product formats. This includes everything from conventional tablets and capsules, both hard and soft gelatin, to more specialized formulations like sachets, liquids, nasal sprays, gels, and topical treatments like ointments and creams. This multifaceted approach allows Strides to effectively meet the demands of diverse patient populations and healthcare providers worldwide. Beyond its generic offerings, Strides Pharma is actively involved in the development and marketing of branded generic products, focusing on therapeutic areas with significant growth potential and unmet medical needs. The company has a particular emphasis on chronic therapies, addressing long-term health conditions that require sustained treatment and management. These strategic therapeutic areas encompass women's health, recognizing the specific healthcare needs of women across different life stages, and the central nervous system, targeting neurological and psychiatric disorders. Furthermore, Strides is committed to developing solutions for cardiovascular ailments, reflecting the increasing prevalence of heart-related diseases globally. This focus on branded generics allows Strides to differentiate itself in the market and provide value-added products for both patients and prescribers. Strides Pharma's strength lies in its ability to integrate research and development, manufacturing excellence, and strategic commercial partnerships to deliver high-quality pharmaceutical products to a global audience. Its vertically integrated structure, encompassing API sourcing, formulation development, and commercialization, enables efficient cost management and robust quality control. The company's commitment to innovation, coupled with its deep understanding of regulatory landscapes across various markets, allows it to navigate the complexities of the pharmaceutical industry effectively. By continuously adapting to evolving market dynamics and investing in future growth opportunities, Strides Pharma Science is positioned to sustain its momentum and expand its reach in the years to come.
Company Details
Key Leadership
Corporate Events
Latest News
STAR Share Price: Frequently Asked Questions
What is the current share price of Strides Pharma Science Ltd?
Strides Pharma Science Ltd (STAR) trades at ₹1106.90 on NSE and BSE. Market cap ₹8.41K (Cr). Educational data only.
What is the P/E ratio of Strides Pharma Science Ltd?
Strides Pharma Science Ltd has a P/E of 19.35x vs industry average 31.77x.
What is the Bull Run score for Strides Pharma Science Ltd?
Strides Pharma Science Ltd has a Bull Run score of 31.7/100 based on 25+ financial parameters.
Does Strides Pharma Science Ltd pay dividends?
Strides Pharma Science Ltd has a dividend yield of 0.44%. Past dividends don't guarantee future payments.
What is the ROE of Strides Pharma Science Ltd?
Strides Pharma Science Ltd has ROE of 150.67%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Strides Pharma Science Ltd?
Strides Pharma Science Ltd has debt-to-equity of 0.67.
Is Strides Pharma Science Ltd a good investment?
Bull Run gives Strides Pharma Science Ltd a score of 31.7/100. This is not investment advice — consult a SEBI-registered advisor.